secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001559053-21-000043
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena reports Q3 net income of $109.2M vs loss; revenue $139.2M on partner payments
--------------------------------------------------------------------------------

- Q3 net income $109.2M ($2.13 diluted EPS) vs net loss $30.6M a year ago; 9-month net income $100.2M.
- Revenue $139.2M, driven by $78.5M BMS option for PRX005 US license and $60.7M IP sale to Novo Nordisk.
- Cash, equivalents and restricted cash $601.5M at Sept 30, 2021; no debt.
- Updated FY2021 guidance: year-end cash ~$575M, net cash from ops/investing $85-95M, net income $50-60M.
- Appointed Tran Nguyen as CFO and Chief Strategy Officer; Brandon Smith as COO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905321000043/0001559053-21-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905321000043/prta-20211104.htm
  HTML page:      https://secwatch.observer/filing/0001559053-21-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer